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Abstract
Background: Many stroke survivors suffer from paresis of lower limb muscles, resulting in compensatory gait patterns
characterised by asymmetries in spatial and temporal parameters and reduced walking capacity. Functional electrical
stimulation has been used to improve walking capacity, but evidence is mostly limited to the orthotic effects of
peroneal functional electrical stimulation in the chronic phase after stroke. The aim of this study is to investigate the
therapeutic effects of up to 10 weeks of multi-channel functional electrical stimulation (MFES)-assisted gait training on
the restoration of spatiotemporal gait symmetry and walking capacity in subacute stroke patients.
Methods: In a proof-of-principle study with a randomised controlled design, 40 adult patients with walking deficits
who are admitted for inpatient rehabilitation within 31 days since the onset of stroke are randomised to either MFES-
assisted gait training or conventional gait training. Gait training is delivered in 30-minute sessions each workday for up
to 10 weeks. The step length symmetry ratio is the primary outcome. Blinded assessors conduct outcome assessments
at baseline, every 2 weeks during the intervention period, immediately post intervention and at 3-month
follow-up.
Discussion: This study aims to provide preliminary evidence for the feasibility and effectiveness of MFES-
assisted gait rehabilitation early after stroke. Results will inform the design of a larger multi-centre trial.
Trial registration: This trial is registered at the Netherlands Trial Register (number NTR4762, registered 28 August 2014)
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Background
Regaining independent gait is considered one of the pri-
mary goals in stroke rehabilitation [1–3]. In the early
phase after stroke, the musculature of the affected side is
often paretic or even paralytic. As a consequence, com-
pensatory gait patterns characterised by asymmetries in
spatial and temporal parameters may arise that tend to
be persistent, even in patients who show substantial res-
toration of paretic leg motor control, perhaps due to
mechanisms related to ‘learned non-use’ as has been de-
scribed for the upper extremity [4]. These compensatory
gait patterns are less energy-efficient and may negatively
affect balance control leading to an increased risk of falls
and injury as well as to limitations in functional mobility
[5–8]. Furthermore, they may cause secondary complica-
tions, such as muscle shortening and joint deformation
[6]. Restoration of gait symmetry can be accomplished by
motor relearning and neuroplasticity, for which highly in-
tensive, repetitive and task-specific training is essential in
the early rehabilitation phase after stroke [9, 10]. The use
of functional electrical stimulation (FES) timed to the gait
cycle in the early phase after stroke may improve gait sym-
metry by enhancing neuroplasticity, preventing secondary
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complications, and by supporting the acquisition of an ad-
equate compensatory strategy. Although the orthotic ef-
fects of peroneal FES (PFES) have been established, the
therapeutic effect of PFES in the subacute phase has been
scarcely investigated [11–19]. Furthermore, PFES assists
the ankle dorsiflexion movement only during the swing
phase and early stance phase of gait and does not support
the more proximal movements of the lower limb. Several
studies have shown that strength and range of motion of
the knee flexors and extensors are associated with gait
performance [20–22]. Thus, multi-channel FES (MFES) of
the distal and proximal parts of the lower limb may be
more effective in normalising the gait pattern by compen-
sating for thigh and dorsiflexor muscle weakness. There is
preliminary evidence of a positive therapeutic effect of
MFES in early stroke rehabilitation on balance control
and mobility [23–25]. However, it remains unclear
whether MFES is effective for the restoration of gait sym-
metry. Furthermore, it remains unclear whether it is feas-
ible to implement MFES in functional gait training
including pre-gait activities. Due to the limited evidence
of MFES-assisted gait training during early stroke rehabili-
tation we designed a proof-of-principle study. The aim of
this study is to examine the feasibility and preliminary
efficacy of MFES-assisted gait training on gait symmetry
and walking capacity in patients in the subacute phase after
stroke during their inpatient rehabilitation. We hypothesise
that MFES-assisted gait training for maximally 10 weeks in
the early phase after stroke is feasible and improves the step
length symmetry compared to conventional gait training. In
this paper we describe the protocol of our study according
to the SPIRIT guidelines (Additional file 1).
Methods
Design
A prospective, assessor-blinded, single-centre, proof-of-
principle study with a randomised controlled two-armed
parallel design is being conducted. Forty participants with
gait impairments in the subacute phase after stroke who
are referred for inpatient rehabilitation are randomly
assigned in a 1:1 ratio to either an intervention group,
receiving MFES-assisted gait training, or a control group,
receiving gait training as usual. The intervention period
lasts 10 weeks or until discharge from inpatient rehabilita-
tion, whichever is sooner. Outcomes will be assessed every
2 weeks during the 10-week intervention period as well as
after a 3-month follow-up period (Fig. 1).
Ethics
The study protocol has been approved by the Medical
Ethics Committee (MEC) of the Academic Medical
Centre Amsterdam (protocol number NL50002.018.14).
Any changes to the study protocol or study procedures
will be reviewed and approved by the MEC and
communicated to relevant parties. A Dutch rehabilita-
tion centre (Merem Rehabilitation Centre De Trappen-
berg in Huizen) granted approval to include and train
participants. The study has been registered at the
Netherlands Trial Register (number NTR4762, registered
28 August 2014). Additional file 2 provides an overview
of the trial registration data.
Participants
Participants are recruited at the rehabilitation centre. All
stroke survivors admitted for inpatient rehabilitation are
screened for eligibility by their physiatrist. Inclusion cri-
teria are: (1) a clinical diagnosis of stroke (diagnostic cri-
teria according to the World Health Organization
definition) [26]; (2) within 31 days since stroke onset; (3)
age between 18 and 80 years; (4) indication for gait
training (according to the treating physiatrist); (5) suffi-
cient capacity to stand between parallel bars with or
without physical assistance and able to walk with aids
and physical assistance from one physical therapist
(Functional Ambulation Categories [FAC] score ≥1); and
(6) passive range of motion (PROM) upon ankle dorsi-
flexion ≥0° with full knee extension. Exclusion criteria
are: (1) subarachnoid haemorrhage or stroke in the cere-
bellum or brain stem; (2) severe spasticity of the knee or
ankle flexors or extensors (i.e., Modified Ashworth Scale
[MAS] ≥ 3); (3) pre-existing lower limb deficits or any
other medical co-morbidities that might significantly
interfere with gait (indicated by a self-reported max-
imum walking distance <300 meter or walking duration
<6 minutes walking pre stroke); (4) severe cognitive
problems or aphasia leading to severely impaired com-
prehension of test instructions; (5) medical conditions
that might lead to inability to comply with the study
protocol (e.g., congestive heart failure, chemotherapy,
uncontrolled epilepsy, pregnancy, depression or psych-
otic disorder, etc.); (6) demand-type cardiac pacemaker,
defibrillator or electrical implant; (7) metallic implant at
the affected lower limb; or (8) present or suspected can-
cerous lesion at the affected lower limb. Potentially eli-
gible participants receive verbal and detailed written
information (see Additional file 3) about the study and
are invited to participate. In case of willingness to par-
ticipate, an intake assessment is performed by a re-
searcher who explains the purpose and procedures of
the study and asks for informed consent. The following
demographics are recorded for each participant: gender,
date of birth, body length, body mass, type of stroke, lo-
cation of stroke (left, right or both), hemiplegic side (left
or right), date of stroke, neglect (tactile and visual
present or not), relevant co-morbidities, medication and
FAC. Furthermore, the following sensorimotor character-
istics of both lower limbs are recorded for each partici-
pant: Motricity Index (muscle strength) [27], Brunnström
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Fugl-Meyer Assessment (motor selectivity) [28], and spe-
cific parts of the Erasmus Medical Centre Modified Not-
tingham Sensory Assessment (tactile and proprioceptive
sensation) [29], MAS (muscle tone) [30, 31] and passive
range of motion at the hip, knee and ankle (PROM). Strat-
egies for patient retention include sending newsletters, ac-
commodating their schedules when planning follow-up
visits, sending reminders of upcoming visits, and provid-
ing transport support.
Randomisation and blinding
Concealed randomisation and allocation is effectuated
by an assigned researcher (AB), who is not involved in
any patient contact, using a computerised randomisa-
tion system. Randomisation takes place stratified by
functional walking capacity (dependent gait [FAC 1–2]
versus independent gait [FAC 3–5]). Outcome asses-
sors are kept blinded to allocation of the participants
during all assessments. Participants are instructed not
to reveal their group allocation or therapy content to
the assessors. Data will be analysed by an independent
statistician. Randomisation will be concealed to the




Participants in the control group will receive regular
gait training by a physical therapist and/or movement
therapist depending on their needs. Typically, per
week, three to eight 30-minute sessions of gait-
oriented physical therapy are given on five working
days for 6 to 12 weeks. This ‘usual care’ may include
individual gait training, gait training in groups, fitness
training, sports, and hydrotherapy. Walking aids,
orthoses, orthopaedic shoes and medication may all
be used, but not lower limb FES. Participants will not
be restricted in their activities. Therapists are
instructed to document characteristics of the gait
training (duration, frequency and content) for each
participant in weekly logs.
Fig. 1 Schedule of enrolment, interventions and assessments
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Intervention group
Participants in the intervention group receive the same
amount of gait-oriented physical therapy, but gait train-
ing is assisted by MFES. Per week, MFES is delivered
during one 30-minute session on five working days up
to 10 weeks. Physical therapists and movement thera-
pists specifically trained in the use of MFES carry out
the gait training. They are instructed to document char-
acteristics of the gait training (duration, frequency, con-
tent and intensity of MFES) for each participant in
weekly logs. During an initial adaptation period of 4 days,
the duration of MFES is gradually increased from 15 mi-
nutes (day 1) to 30 minutes (day 4). Thereafter, partici-
pants receive 30-minute session of MFES-assisted gait
training on each workday.
Multi-channel functional electrical stimulation device
The MFES device used in this study (NESS L300™ Plus,
Bioness, Valencia, CA, USA; CE 0473) delivers electrical
pulses during gait to muscles in the affected leg to pro-
mote ankle dorsiflexion in combination with knee
flexion or extension. The device consists of two cuffs
(lower leg and thigh), a foot switch, and a wireless con-
trol unit that activates the system by radio frequency sig-
nals (Fig. 2). In each cuff two cotton electrodes and a
stimulation unit are embedded. The electrodes of the
lower leg cuff are located over the common peroneal
nerve and the tibialis anterior muscle to elicit ankle
dorsiflexion. The electrodes of the thigh cuff are posi-
tioned over the vastus medialis muscle to promote knee
extension or over the biceps femoris brevis muscle to
promote knee flexion. With this configuration, either
paretic muscles can be stimulated or spastic muscles
antagonised. Figure 3 illustrates some examples of posi-
tioning of the thigh cuff and timing of the upper leg
stimulation expressed as percentage of the gait cycle
[32]. Authorised clinicians are specially trained to fit and
set the MFES device. They fit the device at baseline and
evaluate the settings of the device every two-and-a-half
weeks. A force-sensitive resistor in the foot switch de-
tects the force under the foot. A dynamic gait-tracking
algorithm is used to detect whether the foot is on the
ground (e.g., initial contact) or in the air (e.g., heel off )
by analysing the foot pressure. Average stance and swing
phases are calculated by the system and data is transmit-
ted by radio signals to the stimulation unit allowing for
the synchronisation of the stimulation in accordance
with the timing of gait events (gait mode). During the
fitting process, the clinician sets the stimulation parame-
ters (intensity level, phase duration, pulse rate, waveform
and maximum duration of stimulation, ramp up, exten-
sion and ramp down) for the gait mode with a hand-
held computer (personal digital assistant; PDA). The
peroneal stimulation starts at ‘heel off ’ and terminates at
‘heel contact’. Stimulation can be extended beyond heel
contact to control the first rocker. The thigh stimulation
– biceps femoris brevis or vastus muscles – can start
and end once or twice at any segment in the gait cycle,
which is determined by the clinician. Participants who
cannot walk without personal assistance receive MFES
treatment in the NESS L300™ Plus clinician mode (pre-
gait and balance training) and gait mode (gait training)
during individual physical therapy. The clinician mode is
used to manually start and stop stimulation in the thigh
and lower leg unit simultaneously. The clinician mode
uses the stimulation parameters set for gait mode.
Outcome measures
Primary outcome
The primary outcome to determine efficacy of MFES-
assisted gait training is the step length symmetry ratio.
Step length during comfortable gait is measured with a
spatiotemporal gait analysis system (SGAS) using a lat-
erally placed camera (Panasonic HC-V550 High Defin-
ition camera 50 Hertz; Panasonic, Osaka, Japan) and
discrete linear transform matrix software designed for
this study. Participants walk at comfortable walking
speed along a 10-metre walkway until three valid gait
trials are collected in which each foot lands within the
1300-millimetre-wide video frame for both sides. The
primary condition is walking without shoes and orthosis
with minimal use of walking aids. The symmetry ratio is
calculated as the difference between the step length of
the affected and non-affected leg divided by the mean of
the step length of both legs.
Secondary outcomes
The SGAS is also used to examine other spatiotemporal
parameters (step length, stride length, cadence, stance
time symmetry ratio, double support time, and swing/
stance time symmetry ratio) for two conditions (walking
Fig. 2 The functional electrical stimulation device including two
cuffs, a foot switch, and a control unit
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with and without shoes and orthoses). Furthermore, sa-
gittal and frontal plane video (Basler Scout GigE; Basler
AG, Ahrensburg, Germany), electromyography (Mobita
and Porti 7 8bt; TMSi, Oldenzaal, the Netherlands) and
force plate recordings (OR6-7; AMTI, Watertown, MA,
USA) are used to collect kinematic, electromyographic
and kinetic data, respectively. One valid gait trial is col-
lected for different conditions (walking with and without
shoes, orthoses and walking aids). In addition, at the end
of the intervention period, a full three-dimensional gait
analysis is performed with an 8-camera VICON MX1.3
motion capture system operating at a sample rate of 100
Hertz (VICON, Oxford, United Kingdom) with two
force plates in series recording at 1000 Hertz (OR6-7;
AMTI, Watertown, MA, USA) positioned along a 12-
metre walkway. Three valid gait trials are collected to
register gait width and other kinematic and kinetic pa-
rameters that cannot be determined with the SGAS.
Walking capacity is assessed with the Functional Gait
Assessment (FGA), the FAC and the 10-Meter Walk
Test (10MWT), all validated measurement instruments
in the stroke population [33]. The FGA is a 10-item test
to assess functional gait activities. The FAC is an instru-
ment for categorising gait (in)dependency from ‘no ability
to walk or with the help of two or more persons’ (FAC 0)
to the ‘ability to walk independently’ (FAC 5). The 10MWT
assesses comfortable and maximum walking speed. In this
study, only comfortable walking speed will be recorded.
Walking capacity is also assessed by a subjective walking
capacity recovery score. During each visit the participant is
asked to score his or her recovery of walking capacity since
the onset of stroke by giving a percentage between 0 % (‘no
recovery’) and 100 % (‘full recovery’). Balance control is
assessed with the Berg Balance Scale [34–36] and fear of
falling with the Falls Efficacy Scale I (FES-I) [37].
Feasibility
Feasibility of the intervention is evaluated on the basis of
compliance with the MFES-assisted gait training and pa-
tient satisfaction with this type of training using the MFES
device. The following criteria are used: (1) MFES-assisted
gait training took place during ≥75 % of all therapy ses-
sions; and (2) patient satisfaction with MFES-assisted gait
training was ≥7 on a numeric rating scale from 0 (‘most
unsatisfied’) to 10 (‘most satisfied’) assessed at the end of
the intervention period. Patient satisfaction with the
MFES device is evaluated by a questionnaire designed for
this study.
Sample size
Due to lack of data on effect size, sample size is based on
the feasibility of recruitment in one centre with an ap-
proximate yearly admission rate of 80 stroke survivors.
Using an inclusion period of 3 years and estimating that
25 % of the patients are eligible and willing to participate,
the sample size is set at 40 participants (20 in each group).
Data management and statistical analysis
Data entry takes place by digital and paper case report
forms. Personal information of the participants is treated
confidentially. Every participant receives an identification
number. This number is used on all forms so that no
names or other personal information have to be used.
Data is saved in a locked cabinet in a locked office and
Fig. 3 Examples of thigh cuff muscle activation during the gait cycle
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stored digitally in a trial master file for the duration of
15 years. Data quality is guaranteed by random checks of
the research database and range checks for data values.
Descriptive statistics
Patient characteristics will be described using means,
standard deviations, medians, and interquartile ranges
(dependent on whether data is normally distributed or
not) and percentages. Group comparisons at baseline
will be performed with Student’s t tests, Mann–Whitney
U tests and χ2 tests where appropriate.
Primary and secondary analysis
Primary efficacy analysis will be performed on an
intention-to-treat basis. In addition, per protocol ana-
lyses will be performed. A linear mixed model for re-
peated measures will be used to analyse differences in
the primary outcome and secondary outcomes. A
squared time variable will be included to test for a curvi-
linear recovery curve. The interaction of time by inter-
vention (MFES versus control) assesses whether the
slopes of the recovery curves differ between groups. In
these analyses both the intercept and the time variable
are included as random effects. Group comparisons at
the end of the intervention period for the three-
dimensional gait analysis parameters and FES-I will be
performed with Student’s t tests. To assess feasibility of
the intervention, the proportion of participants in the
intervention group who are compliant with the gait
training and who scored ≥7 on the numeric rating scale
will be determined. Patient satisfaction with the MFES
device will be described. In all analyses, statistical uncer-
tainty will be expressed by means of 95 % confidence in-
tervals. Significance will be set at p < 0.05.
Monitoring and quality assurance
Internal monitoring of the conduct of the study is per-
formed once a year by researchers of the Merem Re-
habilitation Centre De Trappenberg and the Academic
Medical Centre Amsterdam. The completeness, accur-
acy, consistency, and procedures are checked according
to the monitoring plan. Adverse events (AEs) of the in-
dividual participants are reported in the period from
signing informed consent (introduction meeting) until
the last follow-up meeting. All AEs reported spontan-
eously by the participant or observed by the primary re-
searcher or staff are recorded. All AEs are followed until
they have abated or a stable situation has been reached.
Depending on the event, follow-up may require add-
itional tests or medical procedures as indicated, and/or
referral to the general physician or a medical specialist.
Serious AEs (SAEs) are reported up to the end of study.
The sponsor reports the SAEs to the MEC within 15 days
after the sponsor has first knowledge of the SAE. SAEs
that result in death or appear to be life threatening are
reported expedited, i.e. not later than 7 days after the
primary researcher has obtained first knowledge of the
adverse event. The primary researcher reports the pro-
gress of the trial once a year to the MEC.
Dissemination policy
Trial results are communicated to participants, health-
care professionals, the public, and other relevant groups
via newsletters and (inter)national, peer-reviewed jour-
nals (Medline database). The results will be presented at
relevant (inter)national conferences in rehabilitation and
neurology. Furthermore, results will be published on
websites of patient societies.
Discussion
The aim of this study is to evaluate the therapeutic ef-
fects of up to 10 weeks of daily MFES-assisted gait train-
ing on spatiotemporal parameters, walking capacity, and
motor recovery early after stroke. We hypothesise that
stroke survivors will benefit from the therapeutic effect
of MFES-assisted gait training by larger improvements
on spatiotemporal parameters compared to conventional
gait training. These data will inform the design of a suffi-
ciently powered (multi-centre) randomised controlled
trial. The strength of our study is that we investigate the
effects of MFES during functional gait activities. Two
out of three studies investigating MFES in the early
phase after stroke applied MFES with the patient in a
supine position [24, 25]. Moreover, the stimulation pe-
riods in the three studies regarding this topic were only
3–4 weeks [23–25]. There is no evidence for the mini-
mum intensity of MFES required to enhance recovery of
walking capacity in stroke survivors. Different treatment
doses of electrical stimulation have been studied in the
past from 15 minutes up to all day long and from once
to more sessions a day. The three studies investigating
MFES in the early phase after stroke applied MFES for
30–45 minutes and found positive effects on several out-
comes [23–25]. In our study, MFES will be applied each
workday for minimally 15 minutes to maximally 30 mi-
nutes to aim for a feasible protocol in early stroke re-
habilitation. Findings from this study will provide insight
into the initial effects of MFES-assisted gait training on
regaining gait symmetry and several other outcomes in
early stroke rehabilitation. The collection of detailed
data will generate new knowledge regarding early use of
MFES to promote motor and gait recovery in the early
phase after stroke. If this study confirms the feasibility
and initial efficacy of MFES-assisted gait training, a lar-
ger study would be warranted to further determine the
effectiveness of this intervention.
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Trial status
At the time of manuscript submission, the enrolment of
participants was ongoing at Merem Rehabilitation
Centre De Trappenberg, Huizen, the Netherlands.
Additional files
Additional file 1: SPIRIT checklist. (DOC 127 kb)
Additional file 2: Trial registration data. (DOCX 19 kb)
Additional file 3: Dutch information letter and informed consent.
(PDF 284 kb)
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